Mutations in potassium voltage-gated channel subfamily Q member 4 (KCNQ4) are etiologi-
Vazquez, Chen, & Nie, 2013; Kubisch et al., 1999) . As the molecular basis of these diseases is reduction of Kv7 potassium channel activity, resulting from mutations, small compounds that activate these channels, so-called "channel openers," have been developed as a strategy for treatment of these conditions (Wulff, Castle, & Pardo, 2009 ).
Some of these potassium channel openers have been used clinically for the treatment of various neurological disorders, including neonatal epilepsy (Wulff et al., 2009; Xiong, Gao, Wang, & Li, 2008) . KCNQ4 (Kv7.4) is highly expressed in the basal membrane of outer hair cells and mediates the M-potassium current (Kharkovets et al., 2000; Kubisch et al., 1999) . Potassium ions (K + ) are essential for sound transduction in the inner ear. In the cochlea, a K + concentration difference is maintained between the endolymph and the auditory cells in the scala media, and endolymphatic K + flows into the sensory outer hair cells via the apical transduction channel, inducing neurotransmission, and is released from the hair cells into the perilymph via basolateral K + channels, including KCNQ4. Hence, KCNQ4 is crucial for the maintenance of hair cell membrane potential and for K + recycling in the cochlea (Wangemann, 2002) . Kcnq4 −/-mice exhibit progressive hearing loss, with selective degeneration of outer hair cells (Kharkovets et al., 2006) . KCNQ4 is one of the most frequently mutated genes in ADNSHL and, to date, more than 27 mutations in this gene have been reported in the Human Gene Mutation Database (HGMD, http://www.hgmd.
cf.ac.uk/ac/index.php). The KCNQ4 protein consists of six transmembrane domains, a pore region, and two intracellular termini (Dominguez & Dodson, 2012) . The majority of mutations in KCNQ4 linked to hearing loss are clustered around the pore region (Wang et al., 2014) and lead to loss of KCNQ4-mediated potassium currents.
KCNQ4 is assembled in homo-or heterotetramer pore-forming subunits; therefore, defects in a single subunit can impair channel function of the tetramer, explaining the development of hearing loss in individuals heterozygous for KCNQ4 mutations. The majority of mutations have a dominant-negative effect on the wild-type (WT) KCNQ4 protein (Dominguez & Dodson, 2012) ; however, several mutations identified in the N-terminal cytoplasmic region are associated with haploinsufficiency (Coucke et al., 1999; Kamada et al., 2006) .
Here, we identified a new mutation c.140T>C (p.Leu47Pro) in KCNQ4 in four families with progressive hearing loss by whole exome sequencing and examined the pathogenicity of the mutation, using biochemical and electrophysiological assays. We further investigated the effects of KCNQ activators on the activity of potassium channels bearing the mutant protein.
METHODS

Patients and diagnosis of sensorineural hearing loss
This study was approved by the institutional review board of the Severance Hospital, Yonsei University Health System (IRB #4-2015-0659).
We obtained informed written consent from individuals with hearing loss for participation in this study and publication of their clinical data, and enrolled them in the Yonsei University Hearing Loss (YUHL) cohort. All patients who were registered in the YUHL cohort had hearing loss and were referred to Severance Hospital for further evaluation and treatment. Pure tone audiogram and speech audiogram were performed for all patients and their affected and unaffected family members. Pure-tone air (250-8,000 Hz) and bone conduction (250-4,000 Hz) thresholds were measured using clinical audiometers in a double-walled audio booth. The degree of hearing loss was determined by averaging the thresholds of air conduction at 500, 1000, 2000, and 4000 Hz. Auditory steady-state response was also determined for young babies. Temporal bone computed tomogram and magnetic resonance imaging were performed to evaluate inner ear abnormalities.
Whole exome sequencing
Genomic DNA was extracted from peripheral blood obtained from the affected individuals and their parents (whenever available), using RBC Lysis Solution, Cell Lysis Solution, and Protein Precipitation Solution (iNtRon Biotechnology, Inc., Seongnam-si, Korea). Whole exome sequencing and variant filtering were performed as described previously (Jung et al., 2017) , using an Agilent SureSelect V5 enrichment capture kit (Agilent Technologies, Santa Clara, CA, USA) with sequencing on the Illumina HiSeq 2500 platform (101 bases, pairedend). Sequence reads were mapped to the human reference genome assembly (NCBI build 37/hg19) using CLC Genomic Workbench (version 9.5.3) software (Qiagen, Germantown, MD, USA). All variants with a minimum coverage of 2 were used. Variants were called using Basic Variant Caller in CLC Workbench and then annotated.
Plasmid construction and site-directed mutagenesis
Complementary DNAs (cDNAs) for human KCNQ4 were purchased from OriGene Technologies (Rockville, MD, USA) and subcloned into the pENTR-D-TOPO vector (Invitrogen, Carlsbad, CA, USA). Expression vectors with a Myc or FALG-tag in the N-terminus were created using LR clonase (Invitrogen) following the manufacturer's instructions. The c.140T>C (p.Leu47Pro) KCNQ4 clone was generated by PCR-based site-directed mutagenesis, using the Quick change II XL site-directed mutagenesis kit (Agilent Technologies).
Cell culture and transfection
Human embryonic kidney 293 (HEK 293) and Chinese hamster ovary (CHO) cells were cultured in Dulbecco's modified essential medium and RPMI 1640 medium, respectively, supplemented with 10% fetal bovine serum and penicillin (50 IU/ml)/streptomycin (50 g/ml) (Invitrogen). Cells were transfected with WT or mutant KCNQ4 plasmids using Lipofectamine and PLUS reagent, or Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions.
Immunoblotting, immunoprecipitation, surface biotinylation, and immunofluorescence
Experiments were performed as described previously (Gee, Tang, Kim, & Lee, 2010) . Anti-BiP (ab21685), anti--actin (ab6276, Abcam, Cambridge, MA, USA), anti-Myc (sc-40), anti-adolase A1 (sc-12059, Santa Cruz Biotechnology, Dallas, TX, USA), anti-GOLGB1 (HPA011008), and anti-FLAG (F3165, Sigma, St. Louis, MO, USA) antibodies were purchased from commercial sources. Coimmunoprecipitation was performed using EZview Red Anti-FLAG M2 and anti-c-Myc Affinity Gel (Sigma). Surface biotinylation was performed using 0.3 mg/ml EZ-Link Sulfo-NHS-SS-Biotin and NeutrAvidin (Thermo Scientific). Immunoblotting was performed using primary antibodies at 1:1,000 dilution, followed by corresponding anti-isotype secondary antibodies (Santa Cruz Biotechnology) at 1:2,000 dilution.
Signals were visualized using the SuperSignal West-Pico kit (Thermo Scientific). For immunofluorescence, blocking buffer containing 10% donkey serum and 1% bovine serum albumin in phosphate buffered saline was used, and dilutions of primary and fluorophore-tagged secondary antibodies were 1:100 and 1:2,000, respectively. Confocal images were obtained with a Carl Zeiss LSM780 instrument; ZEN software was used for image processing.
Electrophysiology
Potassium channel activities were measured in CHO cells, using the and Origin v. 8.0 (OriginLab Corp., Northampton, MA, USA). Currents were sampled at 5 kHz. All data were low pass-filtered at 1 kHz, and whole cell capacitance was measured in the whole-cell configuration.
The bath solution for the whole-cell patch clamp contained 147 mM NaCl, 5 mM KCl, 1.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, and 10 mM HEPES (titrated to pH 7.4 with NaOH). The pipette solution contained 130 mM KCl, 1 mM CaCl 2 , 3 mM MgATP, 10 mM HEPES, and 10 mM ethylene glycol tetra-acetic acid (EGTA) (titrated to pH 7.2 with KOH). To determine the current-voltage (I-V) relationship, the voltage clamp mode and I-V curve were obtained by applying step pulses from −70 to 40 mV (pulse interval, 10 mV; pulse duration, 2 s; pulse to pulse duration, 20 s; holding potential, -80 mV). KCNQ4 and p.Leu47Pro tail currents were recorded at -50 mV, following prepulses to voltages between -70 and 40 mV. All data presented were normalized to whole cell capacitance (pA/pF). Continuous curves were generated using the Boltzmann function I/I max = (1 + (exp(V 1/2 -V)k m )), where V 1/2 is the half activation voltage, k m = RT/zF is the slope factor, I is the magnitude of the current, and I max denotes the maximum current magnitude.
The kinetics of activation and deactivation of KCNQ4 channels were calculated as described previously (Johnson, Beurg, Marcotti, & Fettiplace, 2011; Schroder et al., 2001 ). The activation of KCNQ4 channels was fitted with a two state double exponential function, according to the following equation I(t) = A fast X (1 -exp(-t/ fast ) + A slow X
(1 -exp(-t/ slow ), where I(t) is the current at time t, A fast and A slow are the current amplitudes at infinite times, and fast and slow are the time constants of the fast and slow components, respectively. The kinetics of deactivation of KCNQ4 channels were fitted with a single exponential function of the form: I(t) = I o X exp(-t/ ), where I o is the peak value of the tail-current, and is the deactivation time constant.
Deactivation currents were analyzed upon returning to -50 mV after currents were elicited by a depolarizing voltage. BMS-204352 (MaxiPost) and zinc pyrithione were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Chemicals
RESULTS
Whole exome sequencing identified a causative mutation in KCNQ4
Currently 405 families have been enrolled in the YUHL cohort. To identify the genetic cause of hearing loss, we have performed whole exome sequencing (WES) for 125 families with hearing loss after GJB2 and SLC26A4, the two most commonly mutated genes for hearing loss in Koreans, were prescreened (Jung et al., 2017) . Among the 125 families, we detected potentially causative mutations in KCNQ4 in six families, indicating that 4.8% (6/125) of the hearing loss cases was caused by KCNQ4. Of these, two families with pathogenic KCNQ4 variants were recently reported (Jung et al., 2018) . Interestingly, four of six families carried the same variant in KCNQ4. In these four families, individuals YUHL48-12, -21, -22; YUHL103-21; YUHL168-21; and YUHL343-21 were subjected to WES ( Figure 1a and Supporting Information Table   S1 ). Based on the pedigrees, autosomal dominant inheritance was suspected in all families ( Figure 1a ). We first examined WES data for nonsynonymous or splice variants in 144 genes known to be linked to hearing loss and found a missense variant c.140T>C (p.Leu47Pro) in KCNQ4, shared by all four families (Table 1; Supporting Information   Table S2 and Figure S1 ). Other variants were identified in known hearing loss genes; however, these were not likely to be causative (Supporting Information Table S2 ). In particular, YUHL48-12 had a heterozygous missense variant in EYA4, c.1922A>G (p.Glu641Gly), but this variant was not shared by YUHL48-22, who also had congenital hearing loss. Rather, this EYA4 variant was shared by YUHL48-21, who did not have congenital hearing loss, suggesting that this variant is likely not pathogenic. In addition, the KCNQ4 variant identified in these four families has not been reported in any public databases, including dbSNP, EPS, or gnomAD (Table 1 ). In addition, this variant was not detected in a whole-genome sequencing dataset of 397 Korean individuals obtained from National Biobank of Korea and from the Centers for Disease Control and Prevention (Table 1 ). The amino acid residue affected by the mutation is evolutionarily conserved down to Danio rerio, other than in Gallus gallus, which has glycine at this position (Supporting Information Figure S1a ). We performed Sanger sequencing to examine whether this KCNQ4 variant segregated with the affected status F I G U R E 1 Pedigrees and audiological phenotypes of individuals with hearing loss. (a) Pedigrees of four independent families are shown. Among the Yonsei University Hearing Loss (YUHL) cohort, families YUHL48, 103, 168, and 343 exhibited an autosomal dominant pattern of hearing loss without syndromic features. Both parents of YUHL48-21 were affected and dominant inheritance was of paternal origin. Note that YUHL48-21 is 3 years old and marked as unaffected. (b) Pure-tone audiograms from individuals from the four affected families. In family YUHL48, individual YUHL48-11 had progressive profound hearing loss, with onset at 41 years old; however, residual hearing was identified at low frequencies. YUHL48-21 did not have congenital hearing loss and showed no audiologic phenotype until 3 years of age, while YUHL48-12 and YUHL48-22 had congenital profound hearing loss without progression. In family YUHL103, a notch of 60-80 dB at 2-4 kHz was identified in YUHL103-11 and YUHL103-21, while auditory function at lower and higher frequencies was normal or mildly affected. In family YUHL168, YUHL168-11 showed high-tone hearing loss, whereas YUHL168-21 had more severe, flat type hearing loss across all frequencies. YUHL343-21 had a progressive hearing loss, which started as a high frequency hearing loss and the age of onset was in the late second decade KCNQ4 from human to Danio rerio has a leucine at the position corresponding to amino acid position 47 of human KCNQ4, whereas the protein from Gallus gallus contains a glycine.
in the four families and found that the variant did indeed cosegregate with the progressive hearing-loss phenotype (Supporting Information Figure S1b ). The c.140T>C (p.Leu47Pro) variant in KCNQ4 identified in this study was submitted to the ClinVar (Variation ID: 585006;
https://www.ncbi.nlm.nih.gov/clinvar/variation/585006/).
As these four families carried the same rare mutation in KCNQ4, we examined the haplotype structure within the 5.5 Mb region flanking the KCNQ4 c.140T>C mutation (hg19 chr1:41,249,905) using our WES data and information from the 1000 Genomes database (Supporting Information Table S3 ). Individuals with the KCNQ4 mutation shared a common haplotype (H1, Supporting Information Table S4 ), suggesting that this mutation may have arisen from a common ancestor in Korea.
Audiological phenotypes and clinical assessment
In family YUHL48, individual YUHL48-11 had moderate bilateral sensorineural hearing loss at the age of 18 years, which progressed to profound hearing loss by the age of 41 years ( Figure 1b) ; however, YUHL48-11 still had residual hearing function at low frequencies, indicating that his audiological phenotype was predominantly high-frequency hearing loss. In contrast, individuals YUHL48-12 and YUHL48-22 had profound congenital deafness. This implies that the audiological phenotype of YUHL48-22 was the same as that of his mother (YUHL48-12), but different from that of his father, in terms of progression and hearing loss onset. Individual YUHL48-21 was only 3 years old, which is too young an age to exhibit the progressive hearing loss phenotype.
In family YUHL103, the affected individuals, YUHL103-11 and YUHL103-21, had a symmetric notch at 2-4 kHz of 60-80 dB while in lower and higher frequencies, the hearing was normal or mildly affected ( Figure 1b ). Both affected individuals showed progressive hearing loss and the age of onset was in the late fourth decade and third decade in YUHL103-11 and YUHL103-21, respectively. The severity of hearing loss was worse in YUHL103-11 than in YUHL103-21, which was correlated with the duration of hearing loss.
In family YUHL168, individual YUHL168-21 had a flat-type hearing loss across all frequencies and hearing loss onset was in the early second decade ( Figure 1b) ; however, the father of YUHL168-21 (YUHL168-11) exhibited high frequency hearing loss, which only affected high frequencies >3 kHz. The onset of hearing loss in YUHL168-11 was in the third decade. Although the duration of hearing loss was longer in YUHL168-11 than in YUHL168-21, the severity of hearing loss was milder and more frequency-specific in YUHL168-11. These data indicate that the audiological phenotype in this family was rather variable.
In family YUHL343, the affected individuals, YUHL343-11 and YUHL343-21, had late onset and high frequency hearing loss, starting in the late second decade. YUHL343-21 showed moderate downsloping hearing loss, which was more severe in the right ear (Figure 1b ).
Individual YUHL343-11 had hearing loss only at frequencies of 4 and 8 kHz, which was milder than that of his son, YUHL343-21. Thus, hearing phenotypes seemed to be variable according to genetic and environmental backgrounds.
Effects of the identified variant on the expression and subunit assembly of KCNQ4
To examine the effect of the identified mutation on transport of KCNQ4 to the plasma membrane, we performed surface biotinylation and immunofluorescence assays to visualize WT and mutant KCNQ4 proteins in HEK 293 cells. The surface biotinylation assay showed that the p.Leu47Pro KCNQ protein reached the plasma membrane and that its expression level was resembling that of WT KCNQ4, when both were overexpressed (Figure 2a ). On immunofluorescence analysis, both WT and p.Leu47Pro KCNQ4 were detected at the cell surface, and co-staining with endoplasmic reticulum and Golgi markers showed that p.Leu47Pro KCNQ4 did not accumulate in these organelles during trafficking to the plasma membrane, similar to WT KCNQ4 ( Figure 2b ).
As the KCNQ4 channel functions as a homo-or heterotetramer of subunits (Coucke et al., 1999) , we examined whether p.Leu47Pro Taken together, these results demonstrate that the p.Leu47Pro
KCNQ4 protein does not exhibit defects in trafficking or subunit assembly.
Effects of the identified mutation on KCNQ4 channel conductance
To examine how the identified KCNQ4 mutation influences voltagegated potassium channel activity, we measured whole cell currents in 
Rescue of p.Leu47Pro KCNQ4 channel activity using channel openers
The potency of several potassium channel openers has been examined and they have been found to successfully potentiate KCNQ4 channels (Leitner et al., 2012) . However, these compounds were not effective when applied to KCNQ4 proteins with mutations in the pore region (Leitner et al., 2012) . As the p.Leu47Pro mutation is located at the cytoplasmic N-terminus, we wondered whether the reduced channel activity of this mutant protein can be rescued by channel openers.
Therefore, we examined the effect of MaxiPost (BMS-204352) and zinc pyrithione on WT and p.Leu47Pro mutant KCNQ4 (Schroder et al., 2001; Xiong, Sun, & Li, 2007) . KCNQ4 was activated by applying depolarizing voltage steps from -70 to +40 mV with 10 mV increments Regarding the channel activation kinetics, the fast activation time constant ( fast ) of p.Leu47Pro KCNQ4 was faster than that of WT, while the slow activation time constants ( slow ) were not different ( 23.50 ± 10.42) was more effective in decreasing fast than zinc pyrithione ( fast: 66.15 ± 14.28) ( Table 2 ). In case of deactivation, p.Leu47Pro KCNQ4 exhibited faster deactivation kinetics than WT protein (Figure 5g ). However, MaxiPost and zinc pyrithione slowed the deactivation of both p.Leu47Pro and WT KCNQ4, thereby making the deactivation kinetics similar (Figure 5h ). Taken together, these data demonstrate that the channel function of the p.Leu47Pro
KCNQ4 protein can almost be completely rescued using channel openers.
DISCUSSION
In this study, we identified a mutation c.140T>C (p.Leu47Pro) in KCNQ4 in four Korean families including individuals with NSHL. Functional studies demonstrated that the identified mutation resulted in reduced voltage-gated potassium channel activity and had a dominant negative effect on WT KCNQ4. Interestingly, the channel activity of the mutant KCNQ4 protein was rescued by the channel openers, MaxiPost and zinc pyrithione.
KCNQ4 is one of the most commonly mutated genes among patients with ADNSHL, particularly those with high frequency hearing loss.
Among more than 27 KCNQ4 mutations reported to date, the majority are in the pore region and cytoplasmic C-terminus of the protein, whereas three (c. c.211delC, map to the cytoplasmic N-terminus (Naito et al., 2013) . All mutations identified in the cytoplasmic N-terminus are frameshift alterations that result in truncated proteins lacking the transmembrane domain and pore region. Currently, the pathogenic mechanism underlying the manifestation of ADNSHL in patients with N-terminal mutations remains unclear. The resulting truncated KCNQ4 proteins are not likely to exert dominant-negative effects; therefore, haploinsufficiency has been suggested to explain the hearing loss phenotypes in individuals with heterozygous KCNQ4 mutations (Coucke et al., 1999; Wang et al., 2014) . The c.140T>C (p.Leu47Pro) mutation identified in this study is the first missense mutation located at the cytoplasmic N-terminus of KCNQ4 and, interestingly, causes reduced channel function. Using whole cell channel recording, we demonstrated that p.Leu47Pro can cause defects in channel kinetics. It is possible that this missense mutation may induce a structural change that hinders gating or narrows pore size; however, the exact mechanism underlying the Compared with mutations in the pore regions, which cause earlyonset and severe hearing loss (Coucke et al., 1999; Van Hauwe et al., 2000) , N-terminal truncating mutations lead to relatively late-onset and mild hearing loss (Coucke et al., 1999; Kamada et al., 2006) . Table S2 and Figure S3 ).
Therefore, it is possible that variants in LOXHD1 act as a modifier of this KCNQ4 mutation, leading to a more severe hearing loss phenotype.
An example in which modifier alleles influence phenotypic variability was previously shown in ciliopathies, a group of inherited diseases that are associated with defects in the primary cilium (Louie et al., 2010) .
Individuals with NPHP1 mutations manifest retinopathy when they also carry a heterozygous AHI1 mutation (Louie et al., 2010) . In addition, in hearing loss digenic inheritance involving GPR98 and PDZ7
was suggested (Kim et al., 2015) , but this needs further validation.
Further investigation is needed to determine whether LOXHD1 and KCNQ4 interact genetically.
An important finding of this study is that p.Leu47Pro KCNQ4 responded to potassium channel openers. Previously, it was demonstrated that KCNQ4 proteins with pore region mutations cannot be restored by a combination of zinc pyrithione and retigabine, whereas KCNQ4 protein harboring a p.Gly321Ser alteration, which is located at the interface of the sixth transmembrane domain and the cytoplasmic C-terminus, is rescuable (Leitner et al., 2012) . The reduced channel activity of p.Leu47Pro KCNQ4 was recovered by both MaxiPost and zinc pyrithione, which increase the probability of KCNQ channel opening by modifying channel gating, rather than through alteration of single channel conductance (Schroder et al., 2001; Xiong et al., 2007) . The fact that these compounds were effective suggests the possibility that the p.Leu47Pro mutation somehow affects channel gating. Another notable point is that the response of p.Leu47Pro KCNQ4 to MaxiPost and zinc pyrithione differed. MaxiPost-induced current, through p.Leu47Pro KCNQ4, exhibited faster activation kinetics than that induced by zinc pyrithione, which showed relatively slower activation kinetics (Table 2) . It is also worthwhile to note that the deactivation time constant of p.Leu47Pro was smaller than that of WT in the absence of an activator (Figure 5g (p.Leu47Pro) mutation. However, although these compounds were shown to be effective in rescuing heterologously expressed KCNQ4, MaxiPost was not effective in potentiating the M-potassium current in outer hair cells, while zinc pyrithione exhibited efficacy in combination with retigabine (Leitner et al., 2012) . In addition, the potassium channel openers developed to date are not specific for KCNQ4 and can activate other KCNQ channels, which could cause unwanted side effects when applied to patients (Wulff et al., 2009; Xiong et al., 2008) .
Therefore, it will be necessary to develop channel openers highly specific for KCNQ4 for clinical application.
In conclusion, by whole exome sequencing of patients with ADNSHL, we identified a new KCNQ4 mutation, c.140T>C (p.Leu47Pro). This mutation is located at the cytoplasmic N-terminus of KCNQ4 and reduces its potassium channel activity; however, its function can be rescued by channel openers, suggesting that individuals with this particular mutation are potentially treatable using these agents. In addition, based on the slowly progressive nature of hearing loss in patients with this KCNQ4 mutation, intervention will be possible if patients undergo early molecular diagnosis.
